Protalix BioTherapeutics names new chairman of board of directors
13 September 2023 -

Biopharmaceutical company Protalix BioTherapeutics Inc (NYSE American: PLX) announced on Tuesday that it has named Eliot Richard Forster PhD as the chairman of the board of directors effective 14 September 2023.

Forster has served on the firm's Nominating Committee.

Presently, Forster is non-executive chairman of Avacta Group PLC (AIM: AVCT), non-executive director of Immatics NV (NASDAQ: IMTX) And non-executive chairman of Ochre Bio, Inc. He has held the position of the chief executive officer of F-Star Therapeutics Ltd, chief executive officer of Immunocure Ltd, chief executive officer of Creabilis SA and president and chief executive officer of Solace Pharmaceuticals Inc. He has also served at Pfizer Global Research & Development and Glaxo/GlaxoWellcome. He is a board member of OSCHR (UK Office for Strategic Coordination of Health Research).

Dror Bashan, Protalix's president and chief executive officer, said: "We are very pleased that Eliot will be joining our Board of Directors. Eliot has an established reputation for management and leadership in the life sciences field with successful experience in the United States, European Union and Asia. He will be a valuable contribution to our Board of Directors as we leverage our development successes to strengthen our research and development efforts."